Spyre Therapeutics (SYRE) Stock Forecast: What Could Drive It in 2026
Short answer
What is actually driving Spyre Therapeutics (SYRE) right now is TL1A pipeline and 2026 catalyst cadence: Spyre's core value driver is its TL1A franchise (SPY002 and SPY072) plus adjacent assets, with roughly six Phase 2 proof-of-concept readouts scheduled across 2026. Product revenue (TTM) is ~$0 (clinical-stage). If that keeps playing out, the setup is favourable; the risk to it is spyre is pre-revenue and unprofitable, with a net loss of roughly $149 million over the trailing twelve months (as of July 2026), so the valuation rests entirely on future clinical success. No one can predict where SYRE trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Spyre Therapeutics (SYRE) higher?
1. TL1A pipeline and 2026 catalyst cadence
Spyre's core value driver is its TL1A franchise (SPY002 and SPY072) plus adjacent assets, with roughly six Phase 2 proof-of-concept readouts scheduled across 2026. Positive early SKYLINE ulcerative colitis data has already validated the platform in investors' eyes. This dense readout calendar means the stock can re-rate quickly, in either direction, on each data drop.
2. Differentiated long-acting dosing
The company engineers antibodies for extended half-life, with SPY001 reported at roughly 4x the half-life of Entyvio and SPY003 near an 85-day half-life. If confirmed in larger trials, less frequent dosing (quarterly or twice-yearly) and combination potential could differentiate Spyre in a crowded IBD field. Convenience and combinability are the commercial thesis if the drugs work.
3. Strong balance sheet funding the plan
Spyre raised capital through an upsized equity offering, lifting cash to roughly $780 million and extending its runway into late 2028. That funds the current slate of Phase 2 trials without a near-term financing cliff. A well-capitalized clinical-stage biotech can pursue multiple shots on goal, though continued dilution remains likely over time.
4. Large IBD and immunology market
IBD and immune-mediated inflammatory diseases represent a multi-billion-dollar market currently served by biologics like Skyrizi, Rinvoq, Entyvio, and Tremfya. Success in even one indication could support meaningful commercial value. The size of the prize is what draws so many competitors into the TL1A race.
What could weigh on SYRE?
Spyre is pre-revenue and unprofitable, with a net loss of roughly $149 million over the trailing twelve months (as of July 2026), so the valuation rests entirely on future clinical success. Its programs are mostly early to mid-stage, and Phase 2 results do not guarantee Phase 3 or approval; a single failed readout among the six planned for 2026 could sharply cut the stock. The TL1A space is intensely competitive, with Merck's tulisokibart already reporting pivotal ulcerative colitis data and Roche, Sanofi/Teva, and others racing ahead, meaning Spyre may reach market later than established rivals. The stock is highly volatile (beta near 3), and further equity raises would dilute holders. Any clinical, regulatory, or safety setback carries outsized downside for a company with no product sales.
Where SYRE trades today
A forecast starts from where the stock actually is. These are SYRE's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for SYRE as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a SYRE forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the SYRE guide and whether SYRE is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the SYRE outlook
The bottom line: what is driving Spyre Therapeutics (SYRE) is TL1A pipeline and 2026 catalyst cadence, with product revenue (ttm) at ~$0 (clinical-stage). If that keeps playing out the setup is favourable; the risk is spyre is pre-revenue and unprofitable, with a net loss of roughly $149 million over the trailing twelve months (as of July 2026), so the valuation rests entirely on future clinical success. No one can predict the price, so treat any SYRE forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around SYRE with Walnut
Use Spyre Therapeutics as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Spyre Therapeutics (SYRE)?
+
No one can reliably predict where SYRE will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Spyre Therapeutics higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive SYRE higher?
+
The main growth drivers are TL1A pipeline and 2026 catalyst cadence; Differentiated long-acting dosing; Strong balance sheet funding the plan. Whether they play out is the real question, not a guaranteed path.
What are the risks to SYRE?
+
Spyre is pre-revenue and unprofitable, with a net loss of roughly $149 million over the trailing twelve months (as of July 2026), so the valuation rests entirely on future clinical success. Its programs are mostly early to mid-stage, and Phase 2 results do not guarantee Phase 3 or approval; a single failed readout among the six planned for 2026 could sharply cut the stock. The TL1A space is intensely competitive, with Merck's tulisokibart already reporting pivotal ulcerative colitis data and Roche, Sanofi/Teva, and others racing ahead, meaning Spyre may reach market later than established rivals. The stock is highly volatile (beta near 3), and further equity raises would dilute holders. Any clinical, regulatory, or safety setback carries outsized downside for a company with no product sales.
Will SYRE stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Spyre Therapeutics's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is SYRE a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the SYRE "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.